MSH3 and colorectal cancer: Loss of MSH3 function is observed in 50% of colorectal cancers as determined by its failed MMR function (EMAST), but also the accumulation of loss of heterozygosity events potentially driven by failed DSB repair at targeted sites in the genome.31